Stifel 2020 Healthcare Conference

RNS Number : 1993F

Renalytix AI PLC

13 November 2020

 

Renalytix AI plc

("RenalytixAI" or the "Company")

RenalytixAI to Participate in the Stifel 2020 Healthcare Conference

NEW YORK, November 13, 2020 - Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today announced the company will be participating in the upcoming Stifel Virtual Healthcare Conference.

RenalytixAI's management is scheduled to present on Tuesday, November 17 at 10:40 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at www.investors.renalytixai.com .  

For further information, please contact:

Renalytix AI plc		www.renalytixai.com
James McCullough, CEO		Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker )		Tel: [phone]
Alex Price / Nicholas Moore
Investec Bank plc (Joint Broker)		Tel: [phone]
Gary Clarence / Daniel Adams
Walbrook PR Limited	Tel: [phone] or  [e-mail]
Paul McManus / Lianne Cawthorne		Mob: [phone]

About Kidney Disease 

Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally.  The Centers for Disease Control and Prevention (CDC) estimates that 15% of US adults, or 37 million people, currently have chronic kidney disease (CKD).  Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and 1 out of 2 people with very low kidney function who are not on dialysis do not know they have CKD*. Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage.  Each year kidney disease kills more people than breast and prostate cancer.  Every day, 13 patients in the United States die while waiting for a kidney transplant.

*  https://www.cdc.gov/kidneydisease/publications-resources/2019-national-facts.html

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. RenalytixAI's products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit www.renalytixai.com .

Disclosure Information

Renalytix AI plc uses filings with the Securities and Exchange Commission, its website ( www.renalytixai.com ), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

 

END

 

 

NRAEAFFAFDNEFAA